Medtronic plc

MDT · Healthcare

$88.01
+0.83% today

What a holder would want to know before buying MDT: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.

Where the price sits
Low $73.75 · Jun 2026High $105.35 · Nov 2025

Today’s price is 20% above the lowest point of the past year and 16% below the highest.

Over the past year it was cheaper than today on 44% of days and more expensive on 56%. Over the last 10 years: cheaper on 49% of days.

Right at its average price of the last 200 trading days.

How bad does it get

Fell 20% or more 3 times in 10 years. The deepest fall was 49%; the longest took 14 months to get back to its peak. 2 of 3 have recovered so far.

It is in one now: 35% below the Sep 2021 peak.

Sep 2021
−49%not back yet
Feb 2020
−40%back in 14 months
Jul 2016
−21%back in 11 months
What you own

Medtronic plc · Healthcare · Medical Devices · a large company worth $113.18B

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three…

Is it making money?
2023
2024
2025
2026

revenue profit

Sales of $36.36B in 2026, with $4.80B of profit. Sales grew in 3 of the last 3 years.

Keeps about 14 cents of every dollar of sales as profit.

Is it healthy?
Cash
$8.82B
Debt
$28.15B
Free cash flow / yr
$5.41B

Would need about 5.2 years of free cash flow to repay all its debt.

Is it expensive?

You pay $22 for every $1 of last year’s profit, and $14 for every $1 of profit expected next year.

A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.

Pays 3.28% a year in dividends at today’s price · next ex-dividend Sep 25.

What others are doing

29 analysts: 19 say buy, 10 hold, 0 sell. Their average 12-month target is $104.44 (range $85.00–$121.00).

Insiders made 0 purchases and 3 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.

Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.

Now try it without risking anything

Poshkan is paper trading: real prices, virtual money. Buy MDT with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.

Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.